About Twist Bioscience
Twist Bioscience is a publicly listed company based in San Francisco (United States) founded in 2013 by Emily Leproust. Synthetic DNA is synthesized via a semiconductor-based platform. Twist Bioscience has raised $245.81 million across 10 funding rounds from investors including Fidelity Investments, Illumina and SVB. The company has 923 employees. Twist Bioscience has completed 3 acquisitions, including Abveris, Genome Compiler Corporation and iGenomX. Its chief executive, as recorded, is Emily Leproust. Its website twistbioscience.com draws about 168 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Amyris, AskBio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.
Company details
Twist Bioscience was founded in 2013 in San Francisco, United States, within the biotechnology sector. A proprietary silicon-based manufacturing process is employed for producing synthetic DNA, applicable in medicine, agriculture, industrial chemicals, and data storage. Synthetic genes, oligo pools, and NGS target enrichment services are provided to facilitate research and development efforts across these fields.
- Annual Revenue$376.57 M (USD)20.32as on Sep 30, 2025
- Net Profit-$77.67 M (USD)62.79as on Sep 30, 2025
- EBITDA-$111.41 M (USD)22.89as on Sep 30, 2025
- Total Equity Funding$245.81M (USD)
in 10 rounds
- Latest Funding Round$50M (USD), Series F
Apr 2018
- InvestorsFidelity Investments
& 20 more
- Employee Count923
- Investments & AcquisitionsAbveris
& 2 more
Apps and channels of Twist Bioscience
its YouTube channel Twist Bioscience has 3.23K subscribers and 30 videos.
Videos from Twist Bioscience
The most watched videos on Twist Bioscience's YouTube channel, Twist Bioscience (3.23K subscribers). Click a video to play it here.
More on Twist Bioscience.
Funding Insights of Twist Bioscience
Twist Bioscience has successfully raised a total of $245.81M across 10 strategic funding rounds. The most recent funding activity was a Series F round of $50 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $245.81M
- Total Rounds 10
- Last Round Series F — $50M
- First Round $9.11M
(Feb 2014)
- Investors Count 21
All 10 funding rounds of Twist Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $50M | Series F | – | – | – |
| Jun 2017 | $27M | Series E | – | – | |
| Mar 2017 | $33M | Series E | – | – | – |
| Apr 2016 | $2.65M | Series D | – | – | – |
| Jan 2016 | $15M | Debt – Conventional | – | – | |
| Jan 2016 | $61.05M | Series D | – | Paladin Capital, Arch Venture Partners | |
| Jun 2015 | $37M | Series C | – | Illumina | |
| Sep 2014 | $10M | Debt – Conventional | – | – | |
| May 2014 | $26M | Series B | – | Joby Pritzker, Nicholas Pritzker | |
| Feb 2014 | $9.11M | Series A | – | – |
21 investors in total: 18 institutional and 3 angel.
Investors in Twist Bioscience
Twist Bioscience has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, Illumina and SVB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech and life sciences focused VC firm investing primarily in the US | biomaticscapital.com | Seattle, United States | ||
Private equity investments are managed across multiple sectors. | 2008 | reinet.com | Luxembourg, Luxembourg | |
| nft-invest.com | ||||
| 3wpcap.com | ||||
| ditchplainscm.com | ||||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital is invested in multiple sectors by Paladin Capital. | paladincapgroup.com | Washington, Dc, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States |
Investor details for Twist Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Twist Bioscience
318 people are tracked at Twist Bioscience (55 in leadership, 6 in board & advisors, 257 in team); the tracked headcount is 923.
| Name | Role | Group |
|---|---|---|
Emily Leproust | Co-Founder & CEO | Leadership |
Dennis Cho | Chief Legal Officer & Corporate Secretary | Leadership |
Tom Asher | Vp, Global Support | Leadership |
Lukas Burlingis | Vp, Corporate Controller | Leadership |
Austin Hsiao | Senior Director, Systems Engineering | Leadership |
Angela Bitting | Chief ESG Officer & SVP, Corporate Affairs | Leadership |
Irene Hoang | Senior Director Of Technology Operations | Leadership |
Siyuan Chen | Chief Technology Officer | Leadership |
Leslie Stanton | Vp, Operations Technology Group, Data Systems | Leadership |
Garry Merry | Executive Director Commercial Operations | Leadership |
Sasank P. | Director, Business Systems | Leadership |
John H. | Director, Human Resource Business Partner | Leadership |
Nara Ramakrishnan | Senior Director Information Technology | Leadership |
Bryan N. Höglund | Director of Applications & Business Development, NGS | Leadership |
Jeremy Dumsday | Sales Director- Kosea | Leadership |
Jimmy Jin | Vice President, Product Management & Marketing | Leadership |
Christina Littler | Senior Director, NGS Product Management | Leadership |
Chris T. | Director of Digital Marketing | Leadership |
Annarose Bednarz | Talent Acquisition Business Partner | Leadership |
Shani Maman | VP of Supply Chain | Leadership |
298 more people are available in the full profile.
Complete people profiles for Twist Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Twist Bioscience
Twist Bioscience is a publicly listed company on the NASDAQ with ticker symbol TWST in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Oct 2018
- Listed onNASDAQ: TWST
- Listed entityTwist Bioscience Corporation
- Exchange sectorHealth technology
- ISINUS90184D1000
- Share price$151.33 (-0.35% on the day) · 2026-10-13
- Market capitalisation$9.96B
- EPS (diluted, trailing year)$-2.22
- Volume (last session)1,529,594
Financials of Twist Bioscience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $376.6M | -$77.7M | -$111.4M |
| 2024 | $313.0M | -$208.7M | -$144.5M |
| 2023 | $245.1M | -$204.6M | -$177.6M |
| 2022 | $203.6M | -$217.9M | -$212.4M |
| 2021 | $132.3M | -$152.1M | -$141.3M |
Detailed financial statements for Twist Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Twist Bioscience
Twist Bioscience has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Abveris, Genome Compiler Corporation and iGenomX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Monoclonal antibodies are discovered rapidly using transgenic rodents. | abveris.com | Quincy, United States | 2014 | Nov 2021 | •••• | |
NGS library construction solutions are provided to enhance DNA sequencing. | igenomx.com | San Diego, United States | 2012 | Jun 2021 | $35M | |
DNA design, visualization, data management, and collaboration tools are provided. | genomecompiler.com | Tel Aviv, Israel | 2011 | Apr 2016 | •••• |
Complete acquisition details for Twist Bioscience
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Twist Bioscience
7 dated milestones of Twist Bioscience across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Twist Bioscience is founded.
- Funding First funding round of $9.1M.
- Acquisition Acquires Genome Compiler Corporation.
- Funding Latest funding round, Series F, of $50.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires iGenomX.
- Acquisition Acquires Abveris.
Competitors of Twist Bioscience
Twist Bioscience has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Ginkgo Bioworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. |
Detailed competitors of Twist Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Twist Bioscience
The website of Twist Bioscience (twistbioscience.com) receives about 167.6K visits a month.
- Monthly visits167.6K
▲ 14.7% vs previous month
Websites whose visitors overlap most with Twist Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| idtdna.com | 100% | 505.8K | #85,096 | View details | |
| benchling.com | 90% | 1.4M | #36,159 | View details | |
addgene.org | addgene.org | 89% | #84,256 | – | |
| biorxiv.org | 87% | 3M | #19,954 | View details | |
| cell.com | 85% | 5M | #14,619 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Twist Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Twist Bioscience (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Twist Bioscience
Complete news archive for Twist Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Twist Bioscience
Twist Bioscience was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Twist Bioscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Emily Leproust is the CEO of Twist Bioscience, as recorded in our data. They have also founded this company.
Twist Bioscience is a funded company, having raised a total of $245.81M across 10 funding rounds to date. The company's 1st funding round was a Series A of $9.11M, raised on Feb 2014.
Twist Bioscience has 923 employees.
Annual revenue of Twist Bioscience is $376.57M as on Sep 30, 2025.
Twist Bioscience was founded in 2013 in San Francisco, United States, within the biotechnology sector. A proprietary silicon-based manufacturing process is employed for producing synthetic DNA, applicable in medicine, agriculture, industrial chemicals, and data storage. Synthetic genes, oligo pools, and NGS target enrichment services are provided to facilitate research and development efforts across these fields.
Twist Bioscience's top competitors include Amyris, AskBio and Ginkgo Bioworks.
Yes, Twist Bioscience is publicly traded on NASDAQ under the ticker symbol TWST.
Twist Bioscience has made 3 acquisitions, including Abveris, Genome Compiler Corporation, and iGenomX.
Twist Bioscience has 21 investors. Key investors include Fidelity Investments, Illumina, SVB, Applied Materials, and FIS.
The website of Twist Bioscience receives about 168 thousand visits a month.